Indian stock news
On July 15, 2026, Sun Pharmaceutical Industries Limited announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for a generic version of a blockbuster oncology medication. The drug, which has an estimated annual market size of $1.2 billion in the US, is expected to be launched immediately. This approval strengthens Sun Pharma's specialty portfolio and is projected to contribute significantly to its margins in the North American market starting from the second quarter of FY27.